Levonorgestrel

DRUG INFORMATION

  ADULT
    - • Release rate of levonorgestrel (LNG) is 17.5 mcg/day after 24 days and declines
      to 7.4 mcg/day after 5 years; Kyleena must be removed or replaced after 5 years.
      Source: US FDA label for levonorgestrel (Kyleena), section 'dosage and
      administration', retrieved 2026-08-29
    - ( 2.3 ) 2.1 Dosing Over Time Kyleena contains 19.5 mg of levonorgestrel (LNG)
      released in vivo at a rate of approximately 17.5 mcg/day after 24 days.
      Source: US FDA label for levonorgestrel (Kyleena), section 'dosage and
      administration', retrieved 2026-08-29
    - This rate decreases progressively to 9.8 mcg/day after 1 year and to 7.4 mcg/day
      after 5 years.
      Source: US FDA label for levonorgestrel (Kyleena), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - No child dose in this label. That usually means untested in children, not
      unsuitable - use a paediatric source.
      Source: Read and found silent: the US FDA label for levonorgestrel (Kyleena),
      retrieved 2026-08-29

  RENAL IMPAIRMENT
    - No kidney-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for levonorgestrel (Kyleena),
      retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - No liver-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for levonorgestrel (Kyleena),
      retrieved 2026-08-29

  PREGNANCY   [ AVOID ]
    The label says not to use it. Read the quote below before deciding.
    - Risk Summary The use of Kyleena is contraindicated in pregnancy or with a
      suspected pregnancy and Kyleena may cause adverse pregnancy outcomes [see
      Contraindications ( 4 ), Warnings and Precautions ( 5.1 , 5.2 )].
      Source: US FDA label for levonorgestrel (Kyleena), section 'pregnancy', retrieved
      2026-08-29
    - If a woman becomes pregnant with Kyleena in place, the likelihood of ectopic
      pregnancy is increased and there is an increased risk of miscarriage, sepsis,
      premature labor, and premature delivery .
      Source: US FDA label for levonorgestrel (Kyleena), section 'pregnancy', retrieved
      2026-08-29
    - Remove Kyleena, if possible, if pregnancy occurs in a woman using Kyleena.
      Source: US FDA label for levonorgestrel (Kyleena), section 'pregnancy', retrieved
      2026-08-29

  BREASTFEEDING
    - Animal reproduction studies have not been conducted with Kyleena. 8.2 Lactation
      Risk Summary Published studies report the presence of LNG in human milk.
      Source: US FDA label for levonorgestrel (Kyleena), section 'use in specific
      populations', retrieved 2026-08-29
    - Small amounts of progestins (approximately 0.1% of the total maternal doses) were
      detected in the breast milk of nursing mothers who used other LNG-releasing IUSs,
      resulting in exposure of LNG to the breastfed infants.
      Source: US FDA label for levonorgestrel (Kyleena), section 'use in specific
      populations', retrieved 2026-08-29
    - There are no reports of adverse effects in breastfed infants with maternal use of
      progestin-only contraceptives.
      Source: US FDA label for levonorgestrel (Kyleena), section 'use in specific
      populations', retrieved 2026-08-29